GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (NAS:XRTX) » Definitions » Selling, General, & Admin. Expense
中文

XORTX Therapeutics (XORTX Therapeutics) Selling, General, & Admin. Expense : $2.15 Mil (TTM As of Sep. 2023)


View and export this data going back to 2018. Start your Free Trial

What is XORTX Therapeutics Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. XORTX Therapeutics's selling, general, & admin. expense for the three months ended in Sep. 2023 was $0.51 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Sep. 2023 was $2.15 Mil.


XORTX Therapeutics Selling, General, & Admin. Expense Historical Data

The historical data trend for XORTX Therapeutics's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XORTX Therapeutics Selling, General, & Admin. Expense Chart

XORTX Therapeutics Annual Data
Trend Feb15 Feb16 Feb17 Dec18 Dec19 Dec20 Dec21 Dec22
Selling, General, & Admin. Expense
Get a 7-Day Free Trial 0.50 0.30 0.62 1.59 2.30

XORTX Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.41 0.51 0.72 0.51

Competitive Comparison of XORTX Therapeutics's Selling, General, & Admin. Expense

For the Biotechnology subindustry, XORTX Therapeutics's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XORTX Therapeutics's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XORTX Therapeutics's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where XORTX Therapeutics's Selling, General, & Admin. Expense falls into.



XORTX Therapeutics Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


XORTX Therapeutics  (NAS:XRTX) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


XORTX Therapeutics Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of XORTX Therapeutics's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


XORTX Therapeutics (XORTX Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.